Abstract
Gene-directed enzyme prodrug therapy (GDEPT) is a promising and emerging strategy that attempts to limit the systemic toxicity inherent to cancer chemotherapy by means of tumor-targeted delivery and expression of an exogenous gene whose product converts nontoxic prodrug(s) into activated cytotoxic agent(s). The bacterial nitroreductase (NTR) enzyme, coupled with its substrate prodrug 5-(azaridin-1-yl)-2,4-dinitrobenzamide (CB1954), is a promising GDEPT strategy that has reached clinical trials. However, no strategy exists to visually monitor and quantitatively evaluate the therapeutic efficacy of NTR/CB1954 prodrug therapy in cells and imaging in living animals. As the success of any GDEPT is dependent upon the efficiency of transgene expression in vivo, we developed a safe, sensitive and reproducible noninvasive imaging method to monitor NTR transgene expression that would allow quantitative assessment of both therapeutic efficacy and diagnostic outcome of NTR/CB1954 prodrug therapy in the future. Here, we investigate the use of a novel fluorescent imaging dye CytoCy5S (a Cy5-labeled quenched substrate of NTR enzyme) on various cancer cell lines in vitro and in NTR-transfected tumor-bearing animals in vivo. CytoCy5S-labeled cells become fluorescent at ‘red-shifted’ wavelengths (638 nm) when reduced by cellular NTR enzyme and remains trapped within the cells for extended periods of time. The conversion and entrapment was dynamically recorded using a time-lapsed microscopy. Systemic and intratumoral delivery of CytoCy5S to NTR-expressing tumors in animals indicated steady and reproducible signals even 16 h after delivery (P<0.001). This is the first study to address visual monitoring and quantitative evaluation of NTR activity in small animals using CytoCy5S, and establishes the capability of NTR to function as an imageable reporter gene.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Accession codes
References
Both GW . Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Curr Opin Mol Ther 2009; 11: 421–432.
Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV . Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009; 14: 4517–4545.
Waerzeggers Y, Monfared P, Viel T, Winkeler A, Voges J, Jacobs AH . Methods to monitor gene therapy with molecular imaging. Methods (San Diego, CA) 2009; 48: 146–160.
Fass L . Imaging and cancer: a review. Mol Oncol 2008; 2: 115–152.
Morris JC, Ramsey WJ, Wildner O, Muslow HA, Aguilar-Cordova E, Blaese RM . A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Hum Gene Ther 2000; 11: 487–503.
Crystal RG, Hirschowitz E, Lieberman M, Daly J, Kazam E, Henschke C et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 1997; 8: 985–1001.
Cunningham C, Nemunaitis J . A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Hum Gene Ther 2001; 12: 1594–1596.
Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol Ther 2009; 17: 1292–1299.
Mailly L, Leboeuf C, Tiberghien P, Baumert T, Robinet E . Genetically engineered T-cells expressing a ganciclovir-sensitive HSV-tk suicide gene for the prevention of GvHD. Curr Opin Investig Drugs 2010; 11: 559–570.
Matthews K, Noker PE, Tian B, Grimes SD, Fulton R, Schweikart K et al. Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer. Clin Cancer Res 2009; 15: 4131–4137.
Wang HE, Yu HM, Liu RS, Lin M, Gelovani JG, Hwang JJ et al. Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer. J Nucl Med 2006; 47: 1161–1171.
Liang Q, Gotts J, Satyamurthy N, Barrio J, Phelps ME, Gambhir SS et al. Noninvasive, repetitive, quantitative measurement of gene expression from a bicistronic message by positron emission tomography, following gene transfer with adenovirus. Mol Ther 2002; 6: 73–82.
Penuelas I, Haberkorn U, Yaghoubi S, Gambhir SS . Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging 2005; 32 (Suppl 2): S384–S403.
Serganova I, Ponomarev V, Blasberg R . Human reporter genes: potential use in clinical studies. Nucl Med Biol 2007; 34: 791–807.
Kang JH, Chung JK . Molecular-genetic imaging based on reporter gene expression. J Nucl Med 2008; 49 (Suppl 2): 164S–179S.
Serganova I, Mayer-Kukuck P, Huang R, Blasberg R . Molecular imaging: reporter gene imaging. Handb Exp Pharmacol 2008; (185 pt 2): 167–223.
Bhaumik S, Lewis XZ, Gambhir SS . Optical imaging of Renilla luciferase, synthetic Renilla luciferase, and firefly luciferase reporter gene expression in living mice. J Biomed Opt 2004; 9: 578–586.
Hoffman RM . Imaging cancer dynamics in vivo at the tumor and cellular level with fluorescent proteins. Clin Exp Metastasis 2009; 26: 345–355.
Luker GD, Piwnica-Worms D . Molecular imaging in vivo with PET and SPECT. Acad Radiol 2001; 8: 4–14.
Wester HJ . Nuclear imaging probes: from bench to bedside. Clin Cancer Res 2007; 13: 3470–3481.
Both GW . Gene-directed enzyme prodrug therapy for cancer: a glimpse into the future? Discov Med 2009; 8: 97–103.
Haberkorn U . PET and SPECT. Handb Exp Pharmacol 2008; (185 Pt 2): 13–35.
Bhaumik S . Advances in imaging gene-directed enzyme prodrug therapy. Curr Pharm Biotechnol 2011; 12: 497–507.
Chung-Faye G, Palmer D, Anderson D, Clark J, Downes M, Baddeley J et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 2001; 7: 2662–2668.
Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, van der Sijp JR et al. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 2004; 22: 1546–1552.
Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI et al. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol 2004; 31: 811–816.
Gambhir SS, Herschman HR, Cherry SR, Barrio JR, Satyamurthy N, Toyokuni T et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2000; 2: 118–138.
Helsby NA, Wheeler SJ, Pruijn FB, Palmer BD, Yang S, Denny WA et al. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. Chem Res Toxicol 2003; 16: 469–478.
Jiang Y, Han J, Yu C, Vass SO, Searle PF, Browne P et al. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation. J Med Chem 2006; 49: 4333–4343.
Kendall JM, Ismail R, Thomas N . Adenoviral sensors for high-content cellular analysis. Methods Enzymol 2006; 414: 247–266.
Bhaumik S, Gambhir SS . Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci USA 2002; 99: 377–382.
Smits AM, van den Hengel LG, van den Brink S, Metz CH, Doevendans PA, Goumans MJ . A new in vitro model for stem cell differentiation and interaction. Stem Cell Res 2009; 2: 108–112.
Acknowledgements
We thank Drs Eric Agdeppa, Steve Lomnes, Mike Cooper, Mark Briggs and Ray Ismail for their invaluable input in developing this new area. We thank Drs Christoph Hergersberg and Kathleen Bove from GE Global Research for their support in writing this manuscript. We also thank Dr Tim Doyle for providing the Imaging facility at Stanford. We thank Dr Sanjiv Sam Gambhir and Dr Chaitali Banerjee for their input in this manuscript. We thank the Department of Radiology, Stanford University for the funding support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on Gene Therapy website
Rights and permissions
About this article
Cite this article
Bhaumik, S., Sekar, T., Depuy, J. et al. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals. Gene Ther 19, 295–302 (2012). https://doi.org/10.1038/gt.2011.101
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2011.101
Keywords
This article is cited by
-
A Highly Selective Fluorescent Probe for the Detection of Nitroreductase Based on a Naphthalimide Scaffold
Journal of Fluorescence (2022)
-
Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging
Gene Therapy (2013)
-
Prodrug enzymes and their applications in image-guided therapy of cancer: tracking prodrug enzymes to minimize collateral damage
Drug Delivery and Translational Research (2012)
-
Emerging Implications of Nonmammalian Cytosine Deaminases on Cancer Therapeutics
Applied Biochemistry and Biotechnology (2012)